Get started

Urothelial Cancer at ESMO 2026

Go beyond the presentations. Discover what resonated with physicians.

Get a complimentary sample of HealthQuant's Next-Generation Congress Intelligence Report, analyzing the clinical findings, physician conversations, and KOL activity that shaped the urothelial cancer landscape at ESMO 2026. And unlike traditional summaries, we identify the findings that matter, the physicians shaping the conversation, and the implications for your strategy.

Designed for Medical Affairs teams, our reports can be customized to your therapeutic area, brand, competitors, and strategic priorities.

Get your complimentary report—fill out the form to download.

Report Cover - Urothelial Cancer at ESMO 2026

What's inside the report

A focused read on what mattered most in Urothelial Cancer at this year's congress.

Congress highlights

The most significant Urothelial Cancer data and presentations from ESMO 2026, distilled into clear takeaways.

Physician & KOL activity

How key opinion leaders engaged with the data, and the conversations shaping clinical perspective.

What it means

Analysis of the trends and signals most relevant to your medical affairs and commercial strategy.

Built for medical affairs teams

If you work in pharmaceutical medical affairs or commercial strategy, this report gives you a clear read on the Urothelial Cancer landscape coming out of ESMO 2026, grounded in HealthQuant's physician influence intelligence.

Download the report